12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lamazym: Phase IIa started

Zymenex began an open-label, dose-escalation, Danish Phase IIa trial to evaluate weekly IV Lamazym for 6 months in 10 patients....

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >